

- **Name:** David Planchard
 - **Current Position & Affiliation:** Head of thoracic group (Institut Gustave Roussy – Villejuif – France)
 - **Country:** France
-

• **Educational Background:**

- 2006-2009: **PhD**, University Paris VII, Fundamental Basis of Oncogenesis – France
- 2006-2007: Post European graduate studies in oncology 2007, University Paris XI – France
- 2006-2007: Oncology's Master 2007, Paris - France
- 2004: Post graduate studies in oncology - France
- 2003: **MD (Medicine)**, Poitiers University Medical School - France

• **Professional Experience:**

- 2007-present: Thoracic Oncologist, Department of Medical Oncology, Gustave Roussy, Villejuif May 2018: Appointed head of the thoracic group
- 2005-2006: Full time hospital practitioner, Thoracic Oncology unit, University Teaching Hospital of Poitiers
- 2003-2005: Assistant Professor of Medicine, Department of Pneumology, University hospital of Poitiers

• **Professional Organizations:**

Department of Medical Oncology, Gustave Roussy, Villejuif

• **Main Scientific Publications:**

1. [Osimertinib plus platinum-pemetrexed in newly diagnosed epidermal growth factor receptor mutation-positive advanced/metastatic non-small-cell lung cancer: safety run-in results from the FLAURA2 study.](#)
Planchard D, Feng PH, Karaseva N, Kim SW, Kim TM, Lee CK, Poltoratskiy A, Yanagitani N, Marshall R, Huang X, Howarth P, Jänne PA, Kobayashi K. ESMO Open. 2021
2. [Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer.](#)
 Li BT, Smit EF, Goto Y, Nakagawa K, Udagawa H, Mazières J, Nagasaka M, Bazhenova L, Saltos AN, Felip E, Pacheco JM, Pérol M, Paz-Ares L, Saxena K, Shiga R, Cheng Y, Acharyya S, Vitazka P, Shahidi J, **Planchard D**, Jänne PA; DESTINY-Lung01 Trial Investigators. N Engl J Med. 2022
3. [Phase 2 Study of Dabrafenib Plus Trametinib in Patients With BRAF V600E-Mutant Metastatic NSCLC: Updated 5-Year Survival Rates and Genomic Analysis.](#)
Planchard D, Besse B, Groen HJM, Hashemi SMS, Mazieres J, Kim TM, Quoix E, Souquet

- PJ, Barlesi F, Baik C, Villaruz LC, Kelly RJ, Zhang S, Tan M, Gasal E, Santarpia L, Johnson BE. *J Thorac Oncol*. 2022
4. [Adjuvant Osimertinib in EGFR-Mutated Non-Small-Cell Lung Cancer.](#)
Planchard D. *N Engl J Med*. 2020
 5. [Circulating Tumor DNA Genomics Reveal Potential Mechanisms of Resistance to BRAF-Targeted Therapies in Patients with BRAF-Mutant Metastatic Non-Small Cell Lung Cancer.](#)
Ortiz-Cuaran S, Mezquita L, Swalduz A, Aldea M, Mazieres J, Leonce C, Jovelet C, Pradines A, Avrillon V, Chumbi Flores WR, Lacroix L, Lorient Y, Westeel V, Ngo-Camus M, Tissot C, Raynaud C, Gervais R, Brain E, Monnet I, Giroux Leprieur E, Caramella C, Mahier-Aït Oukhatar C, Hoog-Labouret N, de Kievit F, Howarth K, Morris C, Green E, Friboulet L, Chabaud S, Guichou JF, Perol M, Besse B, Blay JY, Saintigny P, **Planchard D.** *Clin Cancer Res*. 2020
 6. [ARCTIC: durvalumab with or without tremelimumab as third-line or later treatment of metastatic non-small-cell lung cancer.](#)
Planchard D, Reinmuth N, Orlov S, Fischer JR, Sugawara S, Mandziuk S, Marquez-Medina D, Novello S, Takeda Y, Soo R, Park K, McCleod M, Geater SL, Powell M, May R, Scheuring U, Stockman P, Kowalski D. *Ann Oncol*. 2020
 7. [Postprogression Outcomes for Osimertinib versus Standard-of-Care EGFR-TKI in Patients with Previously Untreated EGFR-mutated Advanced Non-Small Cell Lung Cancer.](#)
Planchard D, Boyer MJ, Lee JS, Dechaphunkul A, Cheema PK, Takahashi T, Gray JE, Tiseo M, Ramalingam SS, Todd A, McKeown A, Rukazenzov Y, Ohe Y. *Clin Cancer Res*. 2019
 8. [Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.](#)
Planchard D, Popat S, Kerr K, Novello S, Smit EF, Faivre-Finn C, Mok TS, Reck M, Van Schil PE, Hellmann MD, Peters S; ESMO Guidelines Committee. *Ann Oncol*. 2018
 9. [Dabrafenib plus trametinib in patients with previously untreated BRAF^{V600E}-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial.](#)
Planchard D, Smit EF, Groen HJM, Mazieres J, Besse B, Helland Å, Giannone V, D'Amelio AM Jr, Zhang P, Mookerjee B, Johnson BE. *Lancet Oncol*. 2017
 10. [Dabrafenib plus trametinib in patients with previously treated BRAF\(V600E\)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial.](#)
Planchard D, Besse B, Groen HJM, Souquet PJ, Quoix E, Baik CS, Barlesi F, Kim TM, Mazieres J, Novello S, Rigas JR, Upalawanna A, D'Amelio AM Jr, Zhang P, Mookerjee B, Johnson BE. *Lancet Oncol*. 2016
 11. [Dabrafenib in patients with BRAF\(V600E\)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial.](#)
Planchard D, Kim TM, Mazieres J, Quoix E, Riely G, Barlesi F, Souquet PJ, Smit EF, Groen HJ, Kelly RJ, Cho BC, Socinski MA, Pandite L, Nase C, Ma B, D'Amelio A Jr, Mookerjee B, Curtis CM Jr, Johnson BE. *Lancet Oncol*. 2016